ambenonium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| quaternary ammonium compounds | 146 | 7648-98-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A quaternary ammonium compound that is an inhibitor of cholinesterase activity with actions similar to those of NEOSTIGMINE, but of longer duration. Ambenonium is given by mouth in the treatment of myasthenia gravis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1112)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 60 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 60.84 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 1, 1956 | FDA | SANOFI AVENTIS US |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N07AA30 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS PARASYMPATHOMIMETICS Anticholinesterases |
| FDA MoA | N0000000177 | Cholinesterase Inhibitors |
| CHEBI has role | CHEBI:37733 | EC 3.1.1.8 inhibitor |
| CHEBI has role | CHEBI:35942 | neurotransmitter agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D002800 | Cholinesterase Inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D010277 | Parasympathomimetics |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| FDA EPC | N0000175723 | Cholinesterase Inhibitor |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Myasthenia gravis | indication | 91637004 | DOID:437 |
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Parkinsonism | contraindication | 32798002 | |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.69 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Acetylcholinesterase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | Kd | 4.34 | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | IC50 | 9.92 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4022236 | VUID |
| N0000020242 | NUI |
| D01001 | KEGG_DRUG |
| 115-79-7 | SECONDARY_CAS_RN |
| 468764 | RXNORM |
| C0002412 | UMLSCUI |
| CHEBI:2627 | CHEBI |
| CHEMBL1652 | ChEMBL_ID |
| DB01122 | DRUGBANK_ID |
| L16PUN799N | UNII |
| 2131 | PUBCHEM_CID |
| 2011 | MMSL |
| 4162 | MMSL |
| d01420 | MMSL |
| 36537006 | SNOMEDCT_US |
| 387197009 | SNOMEDCT_US |
| 46887006 | SNOMEDCT_US |
| D000549 | MESH_DESCRIPTOR_UI |
| CHEMBL1200541 | ChEMBL_ID |
| 4018246 | VANDF |
| 4022236 | VANDF |
| 552 | INN_ID |
| 001706 | NDDF |
| 004686 | NDDF |
Pharmaceutical products:
None